22 COVID-19 vaccines enter clinical trials in China: health official
Xinhua |
Updated: 2021-07-08 19:36
Share
Share - WeChat
BEIJING - Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said Thursday.
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.
- Team formed to investigate the loss of 29 cultural relics
- Investigation into school uniforms confirms safety of waterproof layer
- Taiwan students join winter sports exchange in Tianjin
- World's largest vertical shaft boring machine deployed for cross-river railway tunnel
- Former chairman of State-owned enterprise sentenced to death with two-year reprieve
- Sichuan's ecological restoration attracts record number of migratory birds
